OSD
Projected to reach $105.4 billion by 2030, the global biotechnology and pharmaceutical services outsourcing market is experiencing enormous growth as more pharmaceutical companies than ever before turn to CDMOs to seek the specialist capabilities they need.
There are a number of reasons behind this drive to outsource, including the increased need to collaborate in response to the COVID-19 pandemic. There has also been a significant increase in biotech startups who require the support of outsourcing partners to achieve the development and manufacturing capabilities they may not yet have in-house to bring their discoveries to market.
Despite the advantages of outsourcing, there are challenges facing companies looking to harness the expertise of a contract partner, particularly when it comes to transferring their projects to the partner's site.
These challenges include:
- Meeting client expectations and initial project scope definition
- Product knowledge management
- Standardisation at the receiving site
- Creation and management of dedicated teams
- Transparent communication between originating and receiving sites
In this article with BioPharm International, Lisete Pinto, Product Development and Technical Support Senior Manager at Recipharm, discusses the key pitfalls standing in the way of technology transfer success and the solutions to help overcome them.